Why 2018 Could Be the Best Year Yet for Cara Therapeutics
Most investors would be excited if one of the stocks they owned achieved a 45% gain in less than a year. But for Cara Therapeutics (NASDAQ: CARA) shareholders, that level of performance is somewhat disappointing. Earlier in 2017, the biotech stock was up 190%. However, Cara Therapeutics lost a huge chunk of its market cap after reporting disappointing results in June from a late-stage study of an oral formulation of experimental pain drug CR845.
Is the future now bleak for Cara? I don't think so. Instead, I suspect that 2018 could be the best year yet for the biotech. Here's why.
Image source: Getty Images.
Source: Fool.com
Cara Therapeutics Inc. Aktie
0,29 €
-14,00 %
Cara Therapeutics Inc. erfreut sich mäßiger Beliebtheit, mit mehr Buy- als Sell-Einschätzungen.
Das Kursziel von 4 € für Cara Therapeutics Inc. impliziert eine potenzielle Verdopplung gegenüber dem aktuellen Kurs von 0.29 €.
